HC Wainwright Reaffirms Buy Rating for Imunon (NASDAQ:IMNN)

HC Wainwright reissued their buy rating on shares of Imunon (NASDAQ:IMNN) in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a $14.00 price target on the stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $29.00 price objective on shares of Imunon in a research report on Monday, March 24th.

Imunon Price Performance

Shares of Imunon stock opened at $1.09 on Wednesday. Imunon has a 1 year low of $0.64 and a 1 year high of $3.65. The business has a 50 day moving average price of $0.91 and a 200 day moving average price of $0.92. The company has a market capitalization of $15.94 million, a P/E ratio of -0.58 and a beta of 1.96.

Hedge Funds Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC raised its holdings in Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the period. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.